Specifically, everolimus showed a promising perspective in tumors such as HER2/neu negative advanced breast cancer, bronchial and renal cell carcinoma, unresectable or metastatic neuroendocrine pancreatic tumors, or nonfunctional gastrointestinal and lung-originating ones (1). This evidence concerns the gene ERBB2 and breast carcinoma.